使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by. And welcome to the Intuitive Surgical Q2 2012 earnings release call. At this time, all phone participants are in a listen-only mode. Later, there will be an opportunity for your questions. Instructions will be given at that time. (Operator Instructions) As a reminder, this call is being recorded.
各位女士、先生,感謝您稍候。歡迎參加直覺外科(Intuitive Surgical)2012 年第二季(Q2 2012)財報發布電話會議。此刻,所有電話與會者皆為只聽模式。稍後將提供提問機會。屆時將提供相關指示。(接線員指示)提醒您,本次會議將被錄音。
I would now like to turn the conference over to Calvin Darling, Senior Director Investor Relations for Intuitive Surgical. Please go ahead.
現在我想將會議交給直覺外科投資人關係資深總監 Calvin Darling。請開始。
Calvin Darling - Sr. Dir. IR
Calvin Darling - Sr. Dir. IR
Thank you, and good afternoon. Welcome to Intuitive Surgical's second-quarter conference call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.
謝謝,各位下午好。歡迎參加直覺外科第二季電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及策略規劃副總裁 Aleks Cukic。
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at IntuitiveSurgical.com on the audio archive section under our Investor Relations page. In addition, today's press release has been posted to our website.
在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳加說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。請注意,本次電話會議將可於我們網站 IntuitiveSurgical.com 的「投資人關係」頁面下之音訊存檔區提供重播。此外,今天的新聞稿也已發布於我們的網站。
Today's format will consist of providing you with highlights of our second-quarter's results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second-quarter financial results. Aleks will discuss marketing and clinical highlights. And I will provide an update to our financial forecast for 2012. And finally, we will host a question-and-answer session.
今天的流程將先提供我們第二季業績重點(如今日稍早發布之新聞稿所述),接著進行問答。Gary 將說明本季的業務與營運重點。Marshall 將回顧我們第二季的財務結果。Aleks 將討論行銷與臨床重點。而我將更新我們對 2012 年的財務展望。最後,我們將進行問答環節。
With that, I will turn it over to Gary.
接下來我把時間交給 Gary。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you for joining us today.
感謝各位今天加入我們。
In the second quarter, our team has delivered a solid performance, driven by robust growth in both our US gynecology business and our emerging general surgery business. As a reminder for 2012, Intuitive is focused on the following -- first, continuing our growth in gynecology and urology worldwide, through outstanding execution in the field; second, disciplined execution of our Single-Site and vessel sealing launches, focused on outstanding early customer experiences; third, building robust clinical programs with leading customers in emerging procedures and general surgery, thoracic surgery, and transoral surgery; and, finally, strengthening our capabilities in international markets, particularly Europe, Japan and Korea.
第二季,我們團隊交出穩健表現,主要受惠於美國婦科業務以及新興一般外科業務的強勁成長。提醒各位,2012 年直覺外科聚焦於以下幾點——第一,透過在第一線的卓越執行,持續推動全球婦科與泌尿科的成長;第二,以紀律性方式推進 Single-Site 與血管封合(vessel sealing)產品上市,並聚焦於提供卓越的早期客戶體驗;第三,與領先客戶共同建立強健的臨床計畫,涵蓋新興術式以及一般外科、胸腔外科與經口手術(transoral surgery);最後,強化我們在國際市場的能力,特別是歐洲、日本與韓國。
In the second quarter, we continued to experience strong growth in gynecology and general surgery. Growth in gynecology came from a broad base of procedures, including benign and cancer hysterectomies, sacrocolpopexy, myomectomy and endometriosis resection. Growth in general surgery was also multifaceted, including growth in colon and rectal surgery, as well as cholecystectomy. The latter following the introduction of Single-Site earlier in the year. This strength was tempered somewhat by weakness in Europe and a decline in our US da Vinci prostatectomies. In total, procedures for the second quarter 2012 grew by approximately 26% over the second quarter of 2011. Aleks will provide additional procedure commentary later in the call.
第二季,我們在婦科與一般外科持續呈現強勁成長。婦科成長來自多元術式,包括良性與癌症子宮切除術、薦骨陰道固定術(sacrocolpopexy)、子宮肌瘤切除術(myomectomy)以及子宮內膜異位症切除。一般外科的成長同樣多面向,包括結腸與直腸手術的成長,以及膽囊切除術(cholecystectomy)。後者是在年初推出 Single-Site 之後所帶動。然而,歐洲市場疲弱以及美國達文西前列腺切除術(da Vinci prostatectomies)下滑,部分抵銷了上述強勢表現。整體而言,2012 年第二季手術量較 2011 年第二季約成長 26%。Aleks 稍後將在會議中提供更多手術量相關評論。
Globally, our business in Asia has continued to build, as a result of fine execution by our team. Japan system sales and procedure performance have responded well to MHLW's reimbursement of da Vinci prostatectomy at the start of the second quarter. And we continue to invest in building our capabilities in Japan. Conditions in Europe are challenging, with both broad austerity issues, as well as specific structural issues impacting our business. In response to these conditions, we have brought in an experienced executive from our key accounts group in the United States to lead our European commercial organization. We also continue to invest in our international regulatory and reimbursement teams. Given the depth of environmental issues in Europe, we expect challenging conditions to persist into the second half of the year.
在全球範圍內,我們在亞洲的業務持續建立動能,這歸功於團隊的優異執行。日本的系統銷售與手術量表現,對厚生勞動省(MHLW)於第二季初開始給付達文西前列腺切除術的政策反應良好。我們也持續投資以強化在日本的能力。歐洲的環境充滿挑戰,既有廣泛的財政緊縮問題,也有影響我們業務的特定結構性問題。為因應這些情況,我們從美國關鍵客戶團隊引進一位資深主管,領導我們的歐洲商業組織。我們也持續投資於國際法規與給付(reimbursement)團隊。鑑於歐洲環境問題的深度,我們預期具挑戰性的狀況將延續至下半年。
Turning to operating highlights for the second quarter. Procedures grew approximately 26% over the second quarter of 2011. We sold 150 da Vinci Surgical Systems, up from 129 during the second quarter of last year. Total revenue was $537 million; up 26% over last year. Instrument and accessory revenue increased to $224 million; up 30% over Q2 2011. Total recurring revenue grew to $307 million, up 28% from prior year, and comprising 57% of total revenue. Net income was $155 million; up 32% over last year. We generated an operating profit of $259 million before noncash stock option expense, up 27% from the second quarter of last year. We generated $223 million in gross cash flow from operations and ended the quarter with $2.631 billion in cash and investments.
接著說明第二季的營運重點。手術量較 2011 年第二季約成長 26%。我們售出 150 套達文西手術系統(da Vinci Surgical Systems),高於去年第二季的 129 套。總營收為 5.37 億美元,較去年成長 26%。器械與配件營收增加至 2.24 億美元,較 2011 年第二季成長 30%。總經常性收入(recurring revenue)成長至 3.07 億美元,較前一年成長 28%,並占總營收的 57%。淨利為 1.55 億美元,較去年成長 32%。扣除非現金股票選擇權費用前,我們的營業利益為 2.59 億美元,較去年第二季成長 27%。我們自營運產生的毛現金流為 2.23 億美元,季末現金與投資合計為 26.31 億美元。
Turning to recently-launched products and those in development. In the second quarter, we focused on launches of our Single-Site instruments and Vessel Sealer. We expanded the use of Single-Site cholecystectomy in the US in response to growing early customer demand. Surgeon and patient response to Single-Site has been positive, with over 200 of our US hospital customers having purchased initial Single-Site kits two quarters after launch. As mentioned in prior calls, we are working on expanding our instrument offering in Single-Site to enable its use in additional indications.
接著談近期上市產品與研發中的產品。第二季我們聚焦於 Single-Site 器械與血管封合器(Vessel Sealer)的上市推進。因應早期客戶需求增加,我們在美國擴大 Single-Site 膽囊切除術的使用。外科醫師與病患對 Single-Site 的反應正面;上市兩季後,美國已有超過 200 家醫院客戶購買初始 Single-Site 套件。如同先前電話會議所提,我們正致力於擴充 Single-Site 的器械組合,以便用於更多適應症。
In our vessel sealing launch, we are optimizing procedure choreography through collaboration with leading surgeons, while firming up our manufacturing and supply chain. Clinical response to the Vessel Sealer has been encouraging, with positive commentary on precision, articulation, vessel sealing quality and thermal spread. We expect applications for the da Vinci Vessel Sealer to be centered on general surgery and gynecologic oncology procedures.
在血管封合器的上市推進方面,我們正透過與領先外科醫師合作,優化手術流程編排(procedure choreography),同時強化製造與供應鏈。臨床端對 Vessel Sealer 的回饋令人鼓舞,對其精準度、可動性(articulation)、血管封合品質與熱擴散(thermal spread)均有正面評論。我們預期達文西血管封合器(da Vinci Vessel Sealer)的應用將以一般外科與婦科腫瘤手術為主。
Lastly, with regard to our da Vinci Stapler, we are gathering data to respond to FDA questions, and working on product optimization. As we enter new surgical markets and drive into new product arenas, we continue to invest in building our team and expanding partnerships and in acquiring those technologies that can make a difference to robotic surgery. This quarter, we added 82 people to our team, predominantly in sales, manufacturing, and R&D, bringing our total team to 2,100 employees.
最後,關於我們的達文西吻合器(da Vinci Stapler),我們正在蒐集資料以回應 FDA 的問題,並進行產品最佳化。隨著我們進入新的外科市場並拓展至新的產品領域,我們持續投資於團隊建置、擴大合作夥伴關係,以及取得能為機器人手術帶來差異化的技術。本季我們新增 82 名員工,主要在銷售、製造與研發部門,使員工總數達到 2,100 人。
I'll now pass the time over to Marshall, our Chief Financial Officer.
我現在把時間交給我們的財務長 Marshall。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Thank you, Gary.
謝謝你,Gary。
Our second-quarter revenue was $537 million, up 26%, compared with $426 million for the second quarter of 2011. And up 8% compared with $495 million reported for the first quarter of 2012. Second-quarter revenues by product category were as follows. Second-quarter instrument and accessory revenue was $224 million, up 30% compared with $172 million for the second quarter of 2011 and up 8% compared with $208 million in the first quarter of 2012. The increases in instruments and accessories were driven by procedure growth of approximately 26%, and sales of our new instrument and accessory products including Single-Site, Vessel Sealer, and Firefly.
我們第二季營收為5.37億美元,較2011年第二季的4.26億美元成長26%。並較2012年第一季所報告的4.95億美元成長8%。第二季按產品類別劃分的營收如下。第二季儀器與配件營收為2.24億美元,較2011年第二季的1.72億美元成長30%,並較2012年第一季的2.08億美元成長8%。儀器與配件的成長主要由約26%的手術量成長,以及我們新儀器與配件產品(包括Single-Site、Vessel Sealer與Firefly)的銷售所帶動。
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $2,015 per procedure, which is higher than the $1,940 realized in the second quarter of 2011, and the $1,985 realized in the first quarter of 2012. The increase in I&A per procedure was driven primarily by new product sales in advance of their use in cases.
每例手術實現的儀器與配件營收(包含初始備貨訂單)約為每例2,015美元,高於2011年第二季的每例1,940美元,以及2012年第一季的每例1,985美元。每例手術I&A的增加主要是由新產品在實際用於手術案例之前的預先銷售所驅動。
Second-quarter 2012 systems revenue of $229 million increased 23%, compared with $187 million for the second quarter of 2011, and increased 11% compared with $207 million for the first quarter of 2012. We sold 150 systems in the second quarter of 2012 compared with 129 systems in the second quarter of 2011, and 140 systems in the first quarter of 2012. Our second-quarter average sales price per system was $1.53 million, an increase from the $1.44 million realized in the second quarter of 2011, and $1.47 million realized in the first quarter.
2012年第二季系統營收為2.29億美元,較2011年第二季的1.87億美元成長23%,並較2012年第一季的2.07億美元成長11%。我們在2012年第二季售出150套系統,對比2011年第二季的129套,以及2012年第一季的140套。第二季每套系統平均售價為153萬美元,高於2011年第二季的144萬美元,以及第一季的147萬美元。
ASPs include all da Vinci models, all simulators, and Firefly when configured with the system and exclude upgrades. The increase in ASPs compared with the first quarter of 2012 was driven by favorable channel, product, and trade-in mix. From a channel standpoint, we sold proportionally less systems to distributors, which are sold at lower prices than prices charged to direct customers. There were 14 systems sold to distributors in the second quarter compared with 26 in the first quarter.
ASP包含所有da Vinci機型、所有模擬器,以及在系統配置中包含的Firefly,並排除升級項目。相較2012年第一季,ASP上升主要由有利的通路、產品與以舊換新組合所帶動。就通路而言,我們按比例賣給經銷商的系統較少;經銷商的售價低於對直銷客戶收取的價格。第二季售予經銷商的系統為14套,第一季為26套。
On the product side, we sold 121 simulators, mostly in conjunction with new system sales, compared with 102 last quarter. We also sold 28 dual console systems compared to 25 in the first quarter. 35 of our second-quarter 2012 systems involved trade-ins comprised of 23 da Vinci S's and 12 standard models. While 46 of our first-quarter 2012 system sales involved trade-ins comprised of 27 da Vinci S's and 19 standard models. ASPs will fluctuate quarter to quarter based on product, customer and trade-in mix, as well as foreign exchange rates on direct sales to foreign customers. We would expect system ASPs to decline in future quarters, driven by a return to a more historic mix and lower ASPs earned on direct sales for European customers due to lower Euro exchange rates.
在產品方面,我們售出121台模擬器,多數與新系統銷售一併出售,較上季的102台增加。我們也售出28套雙控制台系統,較第一季的25套增加。2012年第二季的系統銷售中,有35套涉及以舊換新,其中包括23套da Vinci S與12套標準機型。而2012年第一季的系統銷售中,有46套涉及以舊換新,其中包括27套da Vinci S與19套標準機型。ASP將因產品、客戶與以舊換新組合,以及對海外客戶直銷時的外匯匯率而在各季間波動。我們預期未來幾季系統ASP將下滑,主要因回到較具歷史性的組合,以及由於歐元匯率較低,對歐洲客戶直銷所取得的ASP較低。
Service revenue increased $83 million, up 23% compared with $68 million last year, and up 3% compared with $81 million last quarter. The growth in service revenue was primarily driven by a larger system installed base. Total second-quarter recurring revenue comprised of instrument, accessory, and service revenue increased to $307 million, up 28% compared with the second quarter of 2011, and up 6% compared with first quarter of 2012. Recurring revenue represented 57% of total second-quarter revenue compared with 56% in the second quarter last year, and 58% last quarter.
服務營收增加至8,300萬美元,較去年同期的6,800萬美元成長23%,並較上季的8,100萬美元成長3%。服務營收的成長主要由更大的系統裝機基礎所帶動。第二季總經常性營收(由儀器、配件與服務營收構成)增加至3.07億美元,較2011年第二季成長28%,並較2012年第一季成長6%。經常性營收占第二季總營收的57%,相較去年第二季為56%,上季為58%。
International results were as follows. Second-quarter revenue outside the US was $101 million, up 16% compared with revenue of $87 million in the second quarter of 2011, and down 3% compared with revenue of $105 million in the first quarter of 2012. Instrument and accessory revenue grew approximately 21% year-over-year, and decreased 3% sequentially, reflecting procedure growth rates. Procedures outside of the US grew 21% on a year-to-year basis, and decreased approximately 1% sequentially. The growth in procedures compared to the prior year primarily reflect EVP growth in Europe. The decline in procedures compared with the first quarter reflects the macroeconomic environment in Europe, coupled with fewer operating days due to holidays.
國際業績如下。第二季美國以外營收為1.01億美元,較2011年第二季的8,700萬美元成長16%,並較2012年第一季的1.05億美元下滑3%。儀器與配件營收年增約21%,季減3%,反映手術量成長率。美國以外的手術量年增21%,季減約1%。相較前一年,手術量成長主要反映歐洲EVP的成長。相較第一季,手術量下滑反映歐洲的總體經濟環境,加上假期導致可手術天數較少。
EVPs in Japan grew at a high rate, albeit off a small base, as national reimbursement was approved at the beginning of the quarter. We sold 26 systems outside the US compared with 30 in the second quarter of 2011, and 35 last quarter. We sold 13 systems in Europe this quarter, with 16 in the second quarter of 2011, and 14 last quarter. And we sold 7 systems in Japan compared with 7 last quarter, and 4 in the second quarter of last year. The decline in European system sales reflects the difficult macroeconomic environment. Aleks will provide additional details of international system sales.
日本的EVP以很高的速度成長,儘管基期較小,因為全國性給付在本季初獲得核准。我們在美國以外售出26套系統,對比2011年第二季的30套,以及上季的35套。本季我們在歐洲售出13套系統,2011年第二季為16套,上季為14套。我們在日本售出7套系統,與上季同為7套,較去年第二季的4套增加。歐洲系統銷售下滑反映艱困的總體經濟環境。Aleks將提供國際系統銷售的更多細節。
Moving on to the remainder of the P&L, gross margin in the second quarter was 72%, roughly equal to the second quarter of 2011 and the first quarter of 2012. Our gross margin has remained unchanged, as the positive impacts of our higher second-quarter system ASPs were offset by lower margins earned on new products and higher inventory reserves. Margins on newly-launched products will typically be lower than those for our mature products, reflecting vendor pricing on low volumes, temporary tooling costs and other startup costs. Over time, as volumes increase, we refine the manufacturing processes and products, we should see improvement in the margins of these newer products.
接著看損益表其餘項目,第二季毛利率為72%,大致與2011年第二季及2012年第一季相當。我們的毛利率維持不變,因第二季系統ASP較高的正面影響,被新產品較低的毛利率以及較高的存貨備抵所抵銷。新上市產品的毛利率通常會低於成熟產品,反映低出貨量下的供應商定價、暫時性的治具成本及其他啟動成本。隨著時間推移、出貨量增加,以及我們精進製造流程與產品,我們應可看到這些較新產品的毛利率改善。
Second-quarter 2012 operating expenses of $161.1 million were up 16% compared with the second quarter of 2011, and down 1% compared with the first quarter of 2012. We changed our stock option granting pattern this year so that employees are granted options at both February 15 and August 15 compared with only at February 15 in prior years. Although approximately the same number of options will be granted annually, the amount of expense taken in the first quarter and second quarter was approximately $3 million and $5 million lower. And the amount of expense in the third quarter will be approximately $8 million higher than had we not changed our stock granting pattern.
2012年第二季營業費用為1.611億美元,較2011年第二季成長16%,並較2012年第一季下降1%。我們今年調整了員工股票選擇權的授予模式,改為在2月15日與8月15日各授予一次,而過去年度僅在2月15日授予。雖然每年授予的選擇權數量大致相同,但第一季與第二季認列的費用分別約少了300萬美元與500萬美元。而第三季的費用將比未更改授予模式時約多出800萬美元。
We added 82 employees in the quarter, including 38 employees in our commercial operations and 39 employees in product operations. Second-quarter operating income was $225 million, or 42% of sales, compared with $168 million, or 39% of sales for the second quarter of 2011, and $193 million, or 39% of sales for the first quarter of 2012. Second-quarter 2012 operating income reflected $33 million of noncash stock compensation expense compared with $35 million for the second quarter of 2011, and $34 million last quarter.
本季我們新增82名員工,其中商業營運新增38名、產品營運新增39名。第二季營業利益為2.25億美元,占銷售額42%,相較2011年第二季為1.68億美元(占銷售額39%),以及2012年第一季為1.93億美元(占銷售額39%)。2012年第二季營業利益包含3,300萬美元的非現金股票酬勞費用,相較2011年第二季為3,500萬美元,上季為3,400萬美元。
Our effective tax rate for the second quarter was 32% compared with 32% for the second quarter of 2011, and 27% last quarter. Our 32% second-quarter rate was higher than our previous guidance of 31%, primarily due to a higher proportion of pretax income coming from our US business. Our net income was $155 million, or $3.75 per share compared with $117 million, or $2.91 per share for the second quarter of 2011, and $144 million, or $3.50 per share for the first quarter of 2012.
我們第二季的有效稅率為32%,與2011年第二季的32%相同,而上一季為27%。我們第二季32%的稅率高於先前31%的指引,主要因為稅前收入中來自美國業務的占比較高。我們的淨利為1.55億美元,或每股3.75美元,相較於2011年第二季的1.17億美元或每股2.91美元,以及2012年第一季的1.44億美元或每股3.50美元。
Let me quickly summarize our results for the first six months of 2012. Procedures grew by 27%. Total revenue for the first six months of 2012 was $1.32 billion, up 27% compared with $814 million last year. The revenue increase included recurring revenue growth of 29% and an increase in systems revenue of 23%.
我快速總結一下我們2012年前六個月的業績。手術量成長27%。2012年前六個月的總營收為13.2億美元,較去年8.14億美元成長27%。營收增加包含經常性營收成長29%,以及系統營收成長23%。
Operating income for the first six months of 2012 was $419 million, up 32% compared with $316 million last year. Operating income included $68 million of stock-based compensation charges in the first six months of 2012 compared with $67 million in 2011. Net income for the first six months of 2012 was $298 million, or $7.26 per share, compared with $222 million, or $5.51 per share last year. Cash flows from operations for the first six months of 2012 was $383 million, compared with $306 million last year.
2012年前六個月的營業利益為4.19億美元,較去年3.16億美元成長32%。營業利益包含2012年前六個月6,800萬美元的股票基礎薪酬費用,相較於2011年的6,700萬美元。2012年前六個月的淨利為2.98億美元,或每股7.26美元,相較於去年2.22億美元或每股5.51美元。2012年前六個月的營運活動現金流為3.83億美元,相較於去年3.06億美元。
Now moving to the balance sheet. We ended the second quarter with cash and investments of $2.6 billion, up $260 million compared with March 31, 2012. The increase was driven by $217 million of cash flow from operations, plus $56 million from the exercise of stock options, partially offset by $15 million in stock buybacks, and $14 million of capital and IP purchases. We had $553 million board-authorized buybacks remaining. Our accounts receivable balance increased to $323 million at June 30, from $300 million at March 31, primarily reflecting our higher second-quarter revenue. Our net inventory of $119 million at June 30 is equal to the March 31 balance.
接著看資產負債表。我們在第二季末的現金與投資為26億美元,較2012年3月31日增加2.6億美元。增加主要來自營運活動現金流2.17億美元,加上行使股票選擇權帶來5,600萬美元,部分被1,500萬美元庫藏股回購以及1,400萬美元資本與智慧財產(IP)採購所抵銷。董事會授權的回購額度尚餘5.53億美元。我們的應收帳款餘額於6月30日增至3.23億美元,較3月31日的3.00億美元增加,主要反映第二季營收較高。我們6月30日的淨存貨為1.19億美元,與3月31日的餘額相同。
And with that, I would like to turn it over to Aleks, to go over our sales, marketing and clinical highlights.
接下來,我想把時間交給Aleks,請他說明我們在銷售、行銷與臨床方面的重點。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Thank you, Marshall.
謝謝你,Marshall。
During the second quarter, we sold 150 da Vinci systems; 124 in the United States, 13 into Europe, and 13 into rest of world markets. As part of the 150 system sales, 12 standard da Vinci systems, and 23 da Vinci S systems were traded in for credit against sales for new da Vinci Si systems. We had a net 115 system additions to the installed base during the quarter, which brings to 2,341 the cumulative number of da Vinci systems worldwide; 1,707 in the US, 389 in Europe, and 245 in rest of world markets. 79 of the 150 systems installed during the quarter represented repeat system sales to existing customers. In total, 142 of the 150 systems sold represented da Vinci Si systems, which included 28 dual console systems. The 26 system sales internationally included 7 into Japan, 4 into France, and 3 into the UK.
在第二季,我們售出150套達文西(da Vinci)系統;其中124套在美國、13套在歐洲、13套在其他海外市場。在這150套系統銷售中,有12套標準達文西系統與23套達文西S系統以折抵方式換購新的達文西Si系統。本季裝機基數淨增加115套,使全球達文西系統累計達2,341套;其中美國1,707套、歐洲389套、其他海外市場245套。本季安裝的150套系統中,有79套為既有客戶的重複購買。總計而言,售出的150套系統中有142套為達文西Si系統,其中包含28套雙控制台系統。國際市場的26套系統銷售中,包括日本7套、法國4套、英國3套。
Clinically, we had a solid quarter, achieving year-over-year procedure growth of approximately 26%. Gynecology, general surgery, along with the emerging categories of thoracic and head/neck surgery accounted for a large part of this growth. Da Vinci hysterectomy, cholecystectomy, colon and rectal resections, lobectomy, endometriosis resections, myomectomy and partial nephrectomy exhibited strong quarter-over-quarter growth, which was partially offset by DVP softness in the United States. The recent pressure from nonsurgical disease management, namely active surveillance, as well as an apparent decline in PSA screening, has caused some pullback in the US DVP number. As the incumbent leader in the surgical treatment of prostate cancer, it's difficult, perhaps impossible, to remain unaffected by this larger trend, at least in the short-term.
在臨床方面,我們本季表現穩健,手術量年增約26%。婦科、一般外科,以及新興的胸腔與頭頸外科類別,貢獻了這波成長的很大一部分。達文西子宮切除術、膽囊切除術、結腸與直腸切除術、肺葉切除術、子宮內膜異位切除術、肌瘤切除術與部分腎切除術呈現強勁的季增成長,但部分被美國DVP疲弱所抵銷。近期來自非手術疾病管理(即主動監測)的壓力,以及PSA篩檢似乎下降,導致美國DVP數量有所回落。作為前列腺癌外科治療的既有領導者,要不受這個更大趨勢影響是困難的,甚至可能是不可能的,至少在短期內如此。
Recently released new products continue to do well; most notably, Single-Site. Early customer feedback has been positive and our initial sales have been strong. Within the first two quarters, post launch, we sold Single-Site kits to over 200 US customers, while demand for training remains strong. We initiated our phased rollout of the Vessel Sealer product in February. And its use within the segments of general, colorectal and GYN surgery has begun. The product is performing well. And the feature set, specifically the articulated wrist design, appears to be satisfying a strong market need. Operationally, we continue to make progress toward optimizing the manufacturing process, while reducing product cost.
近期推出的新產品持續表現良好;其中最值得一提的是Single-Site。早期客戶回饋正面,我們的初期銷售也很強勁。在上市後的前兩個季度內,我們已向超過200家美國客戶銷售Single-Site套件,而訓練需求仍然強勁。我們於2月啟動Vessel Sealer產品的分階段推廣。其在一般外科、結直腸外科與婦科(GYN)手術等領域的使用已開始。該產品表現良好。其功能組合,特別是可關節式腕部設計,似乎滿足了強烈的市場需求。在營運方面,我們持續朝製造流程最佳化邁進,同時降低產品成本。
Regarding system attachments, namely da Vinci Simulator and da Vinci Firefly. Both attachment rates remained high in the second quarter. Strong market acceptance for these products has helped buoy our da Vinci system ASP to an all-time high.
關於系統附件,也就是達文西模擬器(da Vinci Simulator)與達文西Firefly(da Vinci Firefly)。第二季兩者的附件搭售率都維持在高檔。市場對這些產品的強勁接受度,協助推升我們達文西系統的平均銷售價格(ASP)至歷史新高。
During the quarter, over 350 robotic abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals. And the clinical conferences were abundant with live da Vinci procedure transmissions, postgraduate robotic courses and podium presentations and clinical poster sessions. The adoption of our international DVH business has lagged behind the United States for both malignant and benign conditions. Not surprising.
本季在各類同儕審查期刊中,發表了超過350篇與機器人手術相關的摘要與論文,涵蓋多種外科專科。臨床會議也相當密集,包含達文西手術的現場轉播、研究生階段的機器人課程、口頭報告以及臨床海報展示。我們的國際DVH業務在惡性與良性疾病方面的採用進度,落後於美國。這並不令人意外。
We believe that DVH for the treatment of malignant conditions will likely pace the international GYN business. In a recent addition of the International Journal of Gynecologic Cancers, Doctors Mock and Yang, from the National University in Singapore, published a study describing the conversion of their open hysterectomy practice to a da Vinci hysterectomy practice in treating endometrial cancer. Open surgery is the standard of care for endometrial cancer staging in Singapore, as it is in many other countries. This study compared the results of open hysterectomy to DVH in 124 consecutive endometrial cancer patients. The patients in each cohort were of similar age, BMI, and preexisting health condition. The authors reported that their operating time was longer during their initial 20 DVH procedures, but had dropped significantly thereafter. And were subsequently on par with the comparator. Lymph node harvests were also slightly lower within the initial 20 cases, but were similar thereafter.
我們認為,用於治療惡性疾病的DVH,可能會帶動國際婦科(GYN)業務的步調。在近期一期《International Journal of Gynecologic Cancers》中,新加坡國立大學的Mock與Yang醫師發表研究,描述他們在治療子宮內膜癌時,如何將開腹子宮切除術的臨床實務轉換為達文西子宮切除術的實務。在新加坡,開腹手術是子宮內膜癌分期的標準照護,許多其他國家亦然。該研究比較了124位連續子宮內膜癌患者中,開腹子宮切除術與DVH的結果。兩個隊列的患者在年齡、BMI與既有健康狀況方面相近。作者指出,在最初20例DVH手術中,手術時間較長,但之後顯著下降。並且隨後與對照組相當。淋巴結清掃數在最初20例也略低,但之後相近。
However, DVH was associated with 56% less blood loss than open surgery. It had a lower rate of postoperative complication; 8.8% versus 26.8%. And a lower wound complication rate; 0 versus 9.9%. In addition, the requirement for postoperative parenteral analgesia was only 5.9% for the DVH patients as compared with 51.1% for the open laparotomy patients. And hospitalization was reduced to two days for the DVH patients as compared to 5.9 days for the open laparotomy group. They concluded their paper by stating, and I quote, our series shows that outcomes traditionally associated with laparoscopic endometrial cancer staging are achievable by laparoscopically naive gynecologic cancer surgeons moving from laparotomy to robotic-assisted endometrial cancer staging after a relatively small number of cases, close quote.
然而,DVH的失血量較開腹手術少56%。其術後併發症發生率較低;8.8%對26.8%。且傷口併發症發生率較低;0對9.9%。此外,DVH患者術後需要靜脈(腸外)鎮痛的比例僅5.9%,相較於開腹剖腹手術患者的51.1%。DVH患者住院天數縮短至2天,相較於開腹剖腹手術組的5.9天。他們在論文結論中表示,我引用原文:我們的系列顯示,傳統上與腹腔鏡子宮內膜癌分期相關的結果,對於在腹腔鏡方面缺乏經驗的婦科腫瘤外科醫師而言,在相對少量病例後,從剖腹手術轉換至機器人輔助子宮內膜癌分期亦可達成。引文結束。
Early data for da Vinci Single-Site [co-lease] is being collected at various sites within the US and abroad, while the initial EU publications begin to appear in the literature. In a recent addition of the Archives of Surgery, a consortium made up of five leading Italian robotic centers published initial results of their first 100 Single-Site cholecystectomy procedures. The paper, entitled Overcoming the Challenges of Single Incision Cholecystectomy with Robotic Single-Site Technology, described the contribution of traditional single incision [laparoscomy] as an important development step in moving from multiple site laparoscopy to single-incision interventions. However, single-incision laparoscopic cholocystectomies has not gained widespread use, due in large part to the physical limitations of the technology, which compromises optimal triangulation, the overall ergonomics of the procedure, and quality of view. This, according to the authors.
da Vinci Single-Site[共同租賃]的早期數據正在美國境內及海外各地的多個據點蒐集中,同時,歐盟的初期發表也開始出現在文獻中。在近期一期《Archives of Surgery》中,由五家義大利頂尖機器人中心組成的聯盟,發表了其前100例Single-Site膽囊切除術的初步結果。該論文題為《Overcoming the Challenges of Single Incision Cholecystectomy with Robotic Single-Site Technology》,描述傳統單切口[腹腔鏡]作為從多孔腹腔鏡走向單切口介入的重要發展步驟之貢獻。然而,單切口腹腔鏡膽囊切除術尚未被廣泛採用,主要原因在於技術的物理限制,這會影響最佳三角定位、手術整體人體工學,以及視野品質。作者如是指出。
They also reported that the combination of these factors provides challenges for optimal tissue exposure, and that traditional instruments and platforms have significant limitation when used for SILS. They went on to say, and I quote, da Vinci Single-Site cholecystectomy was regarded as a safe procedure by all surgeons involved in the study, and as safe as standard four-port laparoscopic operations, close quote. They also reported that four out of the five surgeons participating in this trial claimed to be considering the extension of da Vinci Single-Site technology toward treating other conditions.
他們也報告指出,這些因素的組合使得達到最佳組織暴露具有挑戰性,且傳統器械與平台在用於SILS時存在顯著限制。他們接著表示,我引用,所有參與本研究的外科醫師均認為,da Vinci Single-Site膽囊切除術是一項安全的手術,其安全性與標準四孔腹腔鏡手術相當,引用結束。他們亦報告,參與本試驗的五位外科醫師中有四位表示,正考慮將da Vinci Single-Site技術延伸用於治療其他病症。
In their conclusion, they wrote, and I quote, the robotic technology is a compensatory technique that can overcome the constraints and the ergonomic limitations of SILS, and is potentially capable of realizing the full potential of single access approach. We show that it allows for the quick overcoming of the learning curve that is typical of most new procedures, particularly of laparoscopic single-incision approach. This is likely to increase the safety of single-incision surgery, and, in turn, expand adoption to a wider number of general surgeons and surgical procedures, close quote.
在結論中,他們寫道,我引用,機器人技術是一種補償性技術,能夠克服SILS的限制與人體工學上的侷限,並可能實現單一通道入路的全部潛力。我們顯示,它可快速跨越多數新手術常見的學習曲線,尤其是腹腔鏡單切口入路。這很可能提升單切口手術的安全性,並進而擴大至更多一般外科醫師與更多外科手術的採用,引用結束。
In a recent addition of the British Journal of Urology, an interesting paper out of Asia, authored by Dr. Shin Dong-Chung and others from National University Hospital in Taiwan, studied the readmission rates for patients who had undergone open prostatectomy, lap prostatectomy and robotic prostatectomy. The nationwide Taiwanese study included 2,741 patients studied over a five-year period, with the objective of determining the sub 90-day readmission rate associated with each of the three techniques. The reduction of readmission rates is a goal shared by all economies, since the associated costs can be quite significant for payers and patients. In total, 257, or 9.4% of the 2,741 patients studied required a readmission to a hospital within 90 days post surgery. The diagnosis for readmission included intestinal infections, UTIs, hernias, pneumonia, prosthetic hypertrophy, retention of urine, and postoperative infections. The authors reported that the readmission rate for traditional laparoscopic prostatectomy patients was more than twice as common than for patients undergoing a DVP. 8.2% for lap versus 3.6% for DVP.
在近期一期《British Journal of Urology》中,一篇來自亞洲、頗具意思的論文由台灣國立大學醫院的Shin Dong-Chung醫師等人撰寫,研究接受開放式前列腺切除術、腹腔鏡前列腺切除術與機器人前列腺切除術患者的再入院率。這項全台灣的研究納入2,741名患者,追蹤五年,目標是判定三種技術各自對應的術後90天內再入院率。降低再入院率是所有經濟體共同的目標,因為相關成本對付款方與患者而言可能相當可觀。總計而言,在受研究的2,741名患者中,有257人(9.4%)在術後90天內需要再度住院。再入院的診斷包括腸道感染、泌尿道感染(UTI)、疝氣、肺炎、前列腺肥大、尿滯留,以及術後感染。作者報告,傳統腹腔鏡前列腺切除術患者的再入院率,較接受DVP的患者高出兩倍以上。腹腔鏡為8.2%,DVP為3.6%。
When comparing the readmission rate for open prostatectomy to DVP, the frequency of readmission was nearly three times as great; 10.7% versus 3.6%. In their written discussion, the author stated, and I quote, in the present study, we clearly showed that patients undergoing robotic assisted laparoscopic prostatectomy had a lower risk of 90-day readmission than the patients undergoing open prostatectomy. We think that the present study is an important step in helping to define the relative efficacy of robotic prostatectomy, laparoscopic prostatectomy and open prostatectomy, as a treatment option for localized prostate cancer. Moreover, the present findings may prove valuable to patients trying to make an objective decision about the various treatment options. Because the present study used nationwide population-based data sets, its robust findings can be generalized to a population as a whole, close quote.
將開放式前列腺切除術與DVP的再入院率相比,再入院發生頻率幾乎高出三倍;10.7%對3.6%。在其書面討論中,作者表示,我引用,在本研究中,我們清楚顯示,接受機器人輔助腹腔鏡前列腺切除術的患者,其術後90天再入院風險低於接受開放式前列腺切除術的患者。我們認為,本研究是協助界定機器人前列腺切除術、腹腔鏡前列腺切除術與開放式前列腺切除術相對療效的重要一步,作為局部性前列腺癌的治療選項。此外,本研究結果可能對試圖就各種治療選項做出客觀決策的患者具有價值。由於本研究使用全國性、以人口為基礎的資料集,其穩健的研究結果可推廣至整體族群,引用結束。
This concludes my remarks. I'll now turn the time over to Calvin.
以上結束我的發言。接下來把時間交給Calvin。
Calvin Darling - Sr. Dir. IR
Calvin Darling - Sr. Dir. IR
Thank you, Aleks. I will be providing you with an update to our financial forecast for 2012, including procedures, revenues, and other elements of the income statement on a GAAP basis. I will also provide estimates of significant noncash expenses to provide you with visibility into our expected future cash flows.
謝謝你,Aleks。我將向各位提供我們2012年財務預測的最新資訊,包括手術量、營收,以及依GAAP基礎編製的損益表其他項目。我也將提供重大非現金費用的估計,讓各位能掌握我們預期的未來現金流。
Starting with procedures, on our last call, we forecast procedures to grow approximately 25% to 27% from the base of approximately 360,000 procedures performed in 2011. Halfway through 2012, our procedure growth stands at 27%. During the second quarter, we saw continued strength in US gynecology and general surgery procedures, while we experienced a pullback in US DVP volume and challenges in our European procedure business. Based upon the net of these factors, we continue to forecast full-year 2012 da Vinci procedure volume to grow approximately 25% to 27% above our 2011 total.
先從手術量談起。在上次電話會議中,我們預測手術量將在2011年約36萬例的基礎上成長約25%至27%。2012年過了一半,我們的手術量成長為27%。在第二季,我們看到美國婦科與一般外科手術量持續強勁,同時我們也經歷了美國DVP量的回落,以及歐洲手術業務面臨的挑戰。綜合上述因素後,我們仍預測2012年全年da Vinci手術量將較2011年總量成長約25%至27%。
Moving on to revenues. We are increasing our 2012 revenue guidance. Based primarily upon capital sales trends and revenue contributions from new products, we now expect 2012 revenue to grow between 20% and 23% above total 2011 revenue of $1.76 billion. This is up from the 19% to 21% revenue growth forecast on our previous call.
接著談營收。我們上調2012年營收指引。主要基於資本設備銷售趨勢以及新產品帶來的營收貢獻,我們目前預期2012年營收將較2011年總營收17.6億美元成長20%至23%。這高於我們在上次電話會議中預測的19%至21%營收成長。
Specifically related to system ASP, as Marshall mentioned, our Q2 ASP came in at $1.53 million. This metric largely resulted from favorable channel, trade-in, and product mix. Going forward, we would expect to see a system sales mix more in line with previous patterns. In addition, Euro-based system ASPs will be lower in US dollar terms due to the weaker Euro. As a result, we would expect system ASPs to return to more historic levels realized in previous quarters. Overall, we would expect our total Q3 2012 revenue to be near or possibly below our Q2 level.
就系統ASP(平均售價)而言,如Marshall所提,我們第二季ASP為153萬美元。此指標主要來自有利的通路、換購(trade-in)以及產品組合。展望未來,我們預期系統銷售組合將更貼近以往的模式。此外,由於歐元走弱,以歐元計價的系統ASP換算成美元後將較低。因此,我們預期系統ASP將回到前幾季所呈現的較具歷史一致性的水準。整體而言,我們預期2012年第三季總營收將接近,或可能低於第二季水準。
Now, turning to expenses. Consistent with our last call, we continue to forecast full-year noncash compensation to fall within a range of between $152 million and $156 million for the year. The timing of these expenses, however, will be considerably different in 2012 as compared to prior years. As Marshall mentioned, in 2012, we began issuing employee option grants in two installments, one in February and one in August, rather than a single February grant. As a result, in 2012, Q1 and Q2 received lower proportions of the full-year expense. And Q3 will receive a significantly higher proportion. Specifically, 2012 actual stock compensation was $34.4 million in Q1, and $33.3 million in Q2. We would expect Q3 stock compensation to be between $13 million and $14 million higher than Q2, and come in around $47 million, then declining to around $40 million in Q4.
現在談費用。與上次電話會議一致,我們仍預測全年非現金薪酬費用將落在1.52億至1.56億美元之間。然而,這些費用在2012年的認列時點,將與以往年度有相當大的不同。如Marshall所提,2012年我們開始將員工期權授予分兩次發放,一次在2月、一次在8月,而非僅在2月一次性發放。因此在2012年,第一季與第二季分攤到的全年費用占比較低。而第三季將分攤到顯著較高的占比。具體而言,2012年實際股票薪酬費用第一季為3,440萬美元,第二季為3,330萬美元。我們預期第三季股票薪酬費用將較第二季高出1,300萬至1,400萬美元,約為4,700萬美元,之後在第四季下降至約4,000萬美元。
R&D expenses. Based upon the timing of various R&D projects, we anticipate a significant uptick in Q3 R&D expense compared to Q2. Based upon the timing of stock compensation and R&D expenses and continuing business growth, we would expect Q3 operating expenses to come in over $20 million higher than Q2.
研發費用。基於各項研發專案的時程安排,我們預期第三季的研發費用將較第二季顯著上升。基於股權薪酬與研發費用的時點,以及業務持續成長,我們預期第三季營業費用將較第二季高出超過2,000萬美元。
Now, turning to operating income. Consistent with our previous forecast, we continued to expect operating income to fall within a range of between 39% and 40% of net revenue. Again, while second-quarter operating income came at 42% of sales, and we stand at 40.6% on a year-to-date basis, based upon the timing of expenses I just described, we expect full-year operating expense to come in within our 39% to 40% guidance range. We expect other income, which is mainly comprised of interest income, to total between $16 million and $17 million for the year.
接著談營業利益。與我們先前的預測一致,我們仍預期營業利益將落在淨營收的39%至40%區間。再次說明,雖然第二季營業利益為銷售額的42%,且年初至今為40.6%,但基於我剛才描述的費用時點,我們預期全年營業費用將落在我們39%至40%的指引區間內。我們預期其他收入(主要由利息收入構成)全年合計將介於1,600萬至1,700萬美元。
With regard to income tax, our Q2 reported tax rate of 32.4% was above the 31% projection on our last call. While our Q2 tax rate was higher than the forecasted rate, our estimate for Q3 and Q4 remains about the same 31% of pretax income rate. We estimate that our share count for calculating EPS in Q3 2012 will be approximately 41.7 million shares.
就所得稅而言,我們第二季揭露的稅率為32.4%,高於上次電話會議所預估的31%。雖然第二季稅率高於預測,但我們對第三季與第四季的估計仍大致相同,約為稅前所得的31%。我們估計2012年第三季用於計算每股盈餘(EPS)的股數約為4,170萬股。
That concludes our prepared remarks. We will now open the call for your questions.
以上為我們事先準備的發言。接下來我們將開放提問。
Operator
Operator
(Operator Instructions) Ben Andrew with William Blair.
(接線員指示) William Blair 的 Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Gary, maybe give us some insights into DVP trends here and how far you think that may go down. If you can give us some sense of what happened in the quarter. Where does this stabilize, in your view, based on the trends? And it does sound like it's a broader industry shift in the way patients are being managed. Obviously it's becoming less important with the growth of the other pieces, but I just wanted to understand and isolate that bit, if we can.
Gary,能否分享一些關於 DVP 趨勢的看法,以及你認為它可能還會下滑到什麼程度。如果可以,也請讓我們了解本季發生了什麼。依你看,根據這些趨勢,這會在什麼水準趨於穩定?而且聽起來這似乎是整個產業在病患管理方式上的更廣泛轉變。顯然,隨著其他部分的成長,這一塊的重要性在下降,但我只是想了解並把這部分單獨釐清一下,如果可以的話。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes. The way we look at it, it's really being driven by two different effects. One of them has been the scrutiny and discussion around PSA testing and what that impact is. It's hard for us to exactly handicap what the impact on PSA tests and discussion is. But clearly, as one of the major treatment modalities for prostate cancer care, if there are changes to PSA testing and the number of people going into the pipeline, that will flow through to us. And then the second part that you have described has been, if there is a look at nonsurgical treatment modalities and other alternatives, like active surveillance, that also will have an impact.
是的。我們的看法是,這主要由兩個不同的因素所驅動。其中之一是圍繞 PSA 檢測的審視與討論,以及其影響。我們很難精確評估 PSA 檢測及相關討論所帶來的影響。但很明顯地,作為前列腺癌照護的主要治療方式之一,如果 PSA 檢測及進入治療流程的人數出現變化,這會傳導到我們這裡。第二個部分如你所描述的,如果大家轉而檢視非手術治療方式與其他替代方案,例如主動監測(active surveillance),也會產生影響。
Hard for us to predict where that will play out over the long haul. We know, with high confidence, that surgery is the best treatment for men with high-risk prostate cancer. There's really no question. Another question is going to be, as surgical societies and surgeons look at this over the long term, how do they vector patients in through their treatment pathways. What we've seen in the past -- just one more comment -- is that over time, as men are moved into active surveillance, and those come in waves having to do with the amount of publicity it gets, over time, people will start coming back out of active surveillance, either because the cancer is progressing or because over time the active surveillance is in and of itself a burden. So hard to predict with a quantitative sense exactly where that will head. But clearly, those two factors are having an impact on us in the US.
我們很難預測長期會如何發展。我們非常有信心,對於高風險前列腺癌男性而言,手術是最佳治療方式。這點幾乎沒有疑問。另一個問題是,隨著外科學會與外科醫師長期來看待此事,他們會如何在治療路徑中引導病患。我們過去看到的是——再補充一點——隨著男性被轉入主動監測,而這往往會因媒體曝光程度而呈現一波一波的變化;隨著時間推移,人們會開始從主動監測回到治療中,原因可能是癌症惡化,或是長期主動監測本身就成為一種負擔。因此很難以量化方式精確預測未來走向。但很明顯,這兩個因素正在對我們在美國的業務造成影響。
Ben Andrew - Analyst
Ben Andrew - Analyst
Maybe try another way, Gary. Was it down single-digit percentage? Double digit? And what's baked into guidance for the balance of the year?
Gary,換個方式問。它是下降個位數百分比?還是兩位數?而在今年剩餘期間的指引中,已納入哪些假設?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
On our side, it was a significant push. We don't usually break out the numbers for you quarterly. And so we have gone through and done our best to project. It's an estimate. If I had a perfect crystal ball, I would share it with you, but we don't.
就我們這邊而言,這是一個相當明顯的變動。我們通常不會按季把數字拆分給各位。因此我們已盡力做出預測。這是一個估計值。如果我有一顆完美的水晶球,我會跟你分享,但我們沒有。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then you talked about some of the timing of research projects. Maybe give us some insights to what those are. And are we going to see a structural shift in R&D spending, perhaps higher? And also on the operating expense side, can you talk a little bit about opportunities for investment in the sales force? Are you looking to accelerate that, to move things along quicker, maybe offset some of the prostatectomy weakness in other applications? Or are you happy with where the trends are set there?
了解。另外你提到一些研究專案時程的因素。能否分享一下那些是什麼專案。我們是否會看到研發支出在結構上出現變化,例如提高?另外在營業費用方面,你能否談談在銷售團隊投資上的機會?你們是否考慮加速投入、讓進展更快一些,或許用其他應用來抵消前列腺切除術的疲弱?還是你們對目前的趨勢感到滿意?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Fair question. And a lot of questions. The first side, on the R&D and project side, as you know, we have a few things that we have been working on pretty hard. Stapler, you should think of Stapler not as a single product. Stapler will ultimately be a family of products, a platform. That will come out in sequential releases. There's a set of releases and products that make sense for colorectal surgery, a different set that makes sense for thoracic surgery, and a different set that might make sense for bariatric surgery in the future. So those things will move in sequence.
這是個合理的問題。而且問題很多。先談研發與專案面,如你所知,我們有幾項正在非常努力推進的工作。Stapler(縫合器)你不應把它視為單一產品。Stapler 最終會是一個產品家族、一個平台。它將以連續的版本逐步推出。有一組發布與產品適用於大腸直腸手術,另一組適用於胸腔手術,未來還可能有另一組適用於減重(bariatric)手術。因此這些會依序推進。
Likewise Vessel Sealing. Vessel Sealing is a strong instrument for us. Right now it's pointed at general surgery applications and complex gynecologic cancers. But we can see that as being a platform technology, as well. So there are investments here that are sequential. As you know, we also work on Single-Site expansion to other sets of instruments and then other things longer term, in terms of platform improvements.
同樣地,Vessel Sealing(血管封合)。血管封合對我們而言是一項強勢器械。目前主要聚焦於一般外科應用與複雜的婦科癌症。但我們也將其視為一項平台技術。因此這裡的投資是按序進行的。如你所知,我們也在推動 Single-Site(單孔)擴展到其他器械組合,以及更長期的其他事項,例如平台改良。
What I would say is the signal from Q2 to Q3 has more to do with lumpiness and timing than it does a seismic shift in the kind of work we're doing. There is some gradual sequential growth in R&D spend, but mostly what you're seeing is lumpiness.
我想說的是,從第二季到第三季的訊號,更多與波動性與時點有關,而不是我們正在做的工作類型出現劇烈轉變。研發支出確實有一些逐步的序列性成長,但你看到的主要是波動性。
Turning to the question of sales force investments. We are making investments in the sales force. The way you might think about that is significant investments in Japan in terms of our capabilities. We're happy with our team there and they are growing and that will be to allow us to have greater presence over time. We're also making investments in Europe. The investments there are around the sales and commercial team, mostly around bringing in experience and selling and support skills. As well as investments in our ability to respond to regulatory needs and reimbursement and economic analysis needs. So we're making those investments there. They are the kind of investments that are ahead of what you would think of as the US norms. In the US, we continue to invest in the US sales force, although about on pace to what you have seen in past quarters. We don't feel like we are ahead or behind there. But really moving in sync.
再談銷售團隊投資的問題。我們正在對銷售團隊進行投資。你可以這樣理解:我們在日本大幅投資以提升我們的能力。我們對當地團隊很滿意,他們也在成長,這將使我們隨時間推移能有更高的市場能見度。我們也在歐洲進行投資。那裡的投資主要在銷售與商務團隊,重點是引進具備經驗的銷售與支援能力。同時也投資於我們回應法規需求、給付(reimbursement)以及經濟分析需求的能力。因此我們正在那裡進行這些投資。這些投資的性質,會比你認為的美國常態更超前一些。在美國,我們持續投資美國銷售團隊,步調大致與你在過去幾季看到的一樣。我們不覺得在那裡我們是超前或落後。而是基本上同步推進。
Calvin Darling - Sr. Dir. IR
Calvin Darling - Sr. Dir. IR
Specifically, we added about 20 people to our clinical team in the quarter, bringing us up to about 600 on the clinical side. And we stayed roughly flat, about 90, on the capital side.
具體而言,我們在本季度為臨床團隊新增了約20人,使臨床端人數提升至約600人。而在資本端我們大致持平,約90人。
Ben Andrew - Analyst
Ben Andrew - Analyst
If I can sneak in one more quick one. It looks like you had a strong de novo placement effort in the quarter. Talk a little bit about how SIE affected that. I heard the number 200 customers. Are you starting to see a lot of productivity from that in terms of initial cases? And are people actually doing cases beyond [choli] already?
如果我可以再快速補問一題。看起來你們本季度在新設點(de novo)佈署方面表現強勁。能否談談SIE對此的影響?我聽到的數字是200家客戶。就初始病例而言,你們是否開始看到這帶來大量生產力?而且大家是否已經在做超出[choli]的病例了?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I'll just start and Aleks can jump in. On the Single-Site versus SIE, something a little bit different. But with regard to Single-Site, yes, initial purchases, we did say over 200 hospitals in the US have taken their initial kits. We're seeing good utilization so far, although it's early. The response, the commentary in terms of safety and efficacy and repeatability, the ability to learn the procedure quickly, is strong. So we're feeling good about that. But we would caution that we're still in the early quarters there. With regard to people having an interest in doing things beyond cholecystectomy, we're FDA approved in the US for choli. There is surgeon interest O-US, and discussed interest inside the US to do some other things. So we're seeing interest in certain gynecologic procedures, perhaps some upper GI procedures over time. And that's where our R&D teams are spending their time. I'll turn it to Aleks.
我先簡單開頭,Aleks可以再補充。關於Single-Site與SIE,這兩者有些不同。但就Single-Site而言,是的,初始採購方面,我們確實提到美國已有超過200家醫院取得其初始套件。目前我們看到良好的使用率,雖然仍屬早期。在安全性、有效性與可重複性,以及能夠快速學會該手術方面的回饋與評論都很正面。因此我們對此感到樂觀。但我們也要提醒,這仍是在早期的幾個季度。至於是否有人有興趣做超出膽囊切除術的項目,我們在美國針對[choli]已獲FDA核准。在美國以外(O-US)有外科醫師的興趣,美國境內也有人討論想做其他手術。因此我們看到對某些婦科手術的興趣,或許隨時間推進也會有一些上消化道(upper GI)手術。這也是我們研發團隊投入時間的方向。我把時間交給Aleks。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Yes, I would just reiterate, under the comments pertaining to the 200 customers that have purchased initial sites, what we can tell thus far, really, from that is that there is a lot of general interest to try the system. It's too early to make any large clinical claims other than people are looking at improved cosmetics, and then whether or not there's pain differences between one technique versus the other. But at this stage it's very difficult to say. But the interest is high to try it. The training queue is strong. We'll look at it for a few more quarters, I think, before we can assess much more.
是的,我想重申一下,針對已購買初始站點的200家客戶的相關評論,我們目前能夠得出的結論是:大家普遍對嘗試這套系統有很高的興趣。除了人們在觀察外觀改善(cosmetics),以及兩種技術之間是否存在疼痛差異之外,現在還太早,無法提出任何重大的臨床主張。但在這個階段確實很難下定論。不過嘗試的意願很高。培訓排隊需求很強。我想我們還需要再觀察幾個季度,才能做出更多評估。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
In terms of the SIE impact on the quarter, 6 of the 150 systems sold were SIE systems. And to remind you, SIEs, these are three-arm versions of SIs and also have some other feature reductions. And they're primarily targeted towards the more price-sensitive customers who are engaged in the Single-Site, or engaged in maybe lesser complex hysterectomy. I think we are seeing more interest in this particular segment of our product offering.
就SIE對本季度的影響而言,售出的150套系統中有6套是SIE系統。提醒一下,SIE是SI的三臂版本,並且也減少了一些其他功能。它主要鎖定對價格更敏感的客戶,這些客戶可能在做Single-Site,或是從事複雜度較低的子宮切除術。我認為我們確實看到市場對這一產品組合區隔的興趣正在增加。
Ben Andrew - Analyst
Ben Andrew - Analyst
Thank you.
謝謝。
Operator
Operator
Lennox Ketner with Bank of America.
美國銀行(Bank of America)的Lennox Ketner。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
If we could maybe just shift gears and focus on Europe for a minute. I just want to understand, in your view, what's driving the lower procedure growth. I know you talked about it being some structural issues. But in terms of the austerity measures impacting it, what I'm struggling a little bit with, obviously we've seen elective procedures impacted there. Because it's a cancer surgery, I would have thought we would see less. Are you essentially seeing the government just lower their quotas for these surgeries, even though they are cancer surgeries?
如果我們可以換個話題,先把焦點放到歐洲一分鐘。我想了解的是,以你們的觀點,較低的手術量成長是由什麼驅動的。我知道你們提到有一些結構性問題。但就緊縮措施(austerity measures)的影響而言,我有點困惑;顯然我們看到那邊的選擇性手術受到影響。但因為這是癌症手術,我原本以為影響會比較小。你們看到的情況是否本質上是政府即使面對癌症手術,也在降低這些手術的配額?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We definitely see -- it depends on what country you're in. I would start by saying different countries are behaving a little bit differently. So one answer won't cover them all. But taking a couple, as an example. We have seen pressure on quotas. For sure you see total budgets getting pressured and people are making decisions about how they want to spend that money. We think some of it has to do a little bit with how we've grown our organization and their training and skill. If I just stand back from the point of view of bringing clinical and economic value to a procedure that would have been open, and taking it to minimally-invasive da Vinci procedure, we think there's value there. And we think we can do well in the presence of even tight budgets. And that's really the internal part that we're working on.
我們確實看到——這取決於你所在的國家。我會先說,不同國家的表現確實有些差異。所以單一答案無法涵蓋全部。但以幾個國家作為例子。我們確實看到配額受到壓力。你肯定會看到總預算受到擠壓,人們正在決定要如何花這筆錢。我們認為其中一部分也與我們如何擴張組織、以及他們的訓練與技能有關。如果我退一步看,從把原本需要開腹的大型手術,轉為微創的達文西(da Vinci)手術,從臨床與經濟價值的角度來看,我們認為這是有價值的。而且我們認為即使在預算緊縮的情況下,我們也能做得很好。這正是我們正在努力的內部工作重點。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Okay. Just as a follow-up, you had mentioned that you're investing in regulatory and reimbursement issues. Are you focused on changing reimbursement teams in Europe? Or was the reimbursement comment more directed towards Japan?
了解。追問一下,你提到你們正在投資於法規與給付(reimbursement)議題。你們的重點是在歐洲推動給付團隊的變革嗎?還是你提到給付主要是針對日本?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
The answer is a little bit of both. In Japan, it tends to be a more direct conversation with surgical societies and the government. In Europe, it tends to be a little bit more working with surgical societies and health technology assessment groups to really understand the clinical benefits and the long-term, the downstream economic benefits of major surgery. And it's really as a way for hospitals and customers to understand what the total economics are.
答案兩者都有。在日本,通常是與外科醫學會及政府進行較直接的對話。在歐洲,則更偏向與外科醫學會及健康科技評估(HTA)團體合作,以真正理解臨床效益,以及重大手術在長期、下游的經濟效益。這也讓醫院與客戶能理解整體經濟性(total economics)是什麼。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Okay. And then just last question on the Single-Site. The attachment for that, is it possible to give us some sense of when a hospital does buy the Single-Site attachment, how much you're charging for that? And is that revenue recorded as part of an upgrade revenue, or is that in instruments and accessories?
了解。最後一題關於Single-Site。關於該附件(attachment),是否可以讓我們了解一下,當醫院購買Single-Site附件時,你們大概收費多少?而這筆收入是記錄在升級收入(upgrade revenue)中,還是記在器械與耗材(instruments and accessories)?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Just to let everyone know, the Single-Site is a set of instruments that attach to the da Vinci Si system. And so there's no system upgrade required to do Single-Site procedures. Usually, initial customers, you need to have the 8.5-millimeter endoscopes, as well as the specific instruments for the case and so on. On average out of the gate, it might be something like a $40,000 investment to get going. It's recorded on the instrument and accessory line.
先讓大家知道,Single-Site是一組可連接到達文西Si系統的器械。因此要做Single-Site手術不需要進行系統升級。通常對於初始客戶,你需要8.5毫米內視鏡,以及該病例所需的特定器械等等。平均來說,一開始要啟動可能需要約4萬美元的投資。這會記錄在器械與耗材項下。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Okay, got it. Thanks so much. I'll let someone else jump in.
好的,了解。非常感謝。我讓其他人接著問。
Operator
Operator
Tycho Peterson with JPMorgan.
摩根大通(JPMorgan)的Tycho Peterson。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
I want to go back to the discussion on DVP from before and understand obviously with the change in screening intervals, that's one aspect. But as we think about watchful waiting, do you have any color on what the conversion factor is in terms of patients going into watchful waiting and then coming back and having surgery? And obviously with PIVOT back in the news, is there anything you need to do differently in terms of data generation or marketing, given that it's back in the public press, if you will?
我想回到先前關於DVP的討論。顯然篩檢間隔的改變是一個面向。但當我們思考「觀察等待」(watchful waiting)時,你們能否提供一些資訊:就進入觀察等待、之後再回來接受手術的病患而言,其轉換比例(conversion factor)大概是多少?另外,PIVOT又回到新聞焦點,你們在數據產出或行銷方面,是否需要做任何不同的調整,鑑於它再次出現在大眾媒體上?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I'll speak to the first one, and let Aleks speak to the second one. With regard to what the behavior has been historically with regard to people in active surveillance, in very rough outlines, it's been about one-third starting active surveillance and staying in active surveillance throughout. About one-third will convert to aggressive disease and in essence be kicked out by progression. And about one-third will choose to leave because of the repeated going back into being tested. At some point they decide they would rather have a definitive treatment. And that's been historical. It's rough and we'll see if it holds going forward.
我先回答第一個,第二個讓Aleks來回答。就歷史上對於處於主動監測(active surveillance)的人群之行為而言,粗略來看,大約三分之一開始主動監測並且全程都維持在主動監測。約三分之一會轉變為侵襲性疾病,基本上會因病程進展而被迫退出。另外約三分之一會因為反覆回去接受檢測而選擇離開。在某個時間點,他們會決定寧可接受明確的治療。這一直是過去的情況。這只是粗略估計,我們會看看未來是否仍然成立。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
With regard to the second part of your question, the PIVOT trial being back in the news. I don't know that there was anything that was new that was reported today. I think this is something that we've discussed, I think, over the past year, since it had been presented at the AUA. I think the editorial that accompanied the actual report in the New England Journal of Medicine really says, I think, has a pretty consistent tone to the way we think about it, as well.
至於你問題的第二部分,PIVOT試驗又回到新聞焦點。我不確定今天報導的內容是否有任何新的資訊。我想這是我們在過去一年裡討論過的事情,因為它在AUA上發表之後我們就一直在談。我認為《新英格蘭醫學期刊》(New England Journal of Medicine)正式報告所附的社論,確實也以相當一致的語氣表達了我們對此的看法。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then just to clarify your comments on Europe, I'm not understanding why the volumes are really declining here when you've got nationalized healthcare in a lot of these markets. Is it really that variable in these geographies?
另外,為了釐清你對歐洲的評論,我不太理解為什麼在這裡的量真的在下滑,因為這些市場中有很多都有國民醫療。這些地理區域之間真的差異那麼大嗎?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Short answer is yes, it's variable. You have a few different things. And, again, I think you have to think, what's happening in Italy, what's happening in Spain, what's happening in Germany, what's happening in France, what's happening in the UK, what's happening in the Scandinavian countries. And they vary. In many of the countries, you have a combination of private health systems and public ones. Their behaviors vis-a-vis da Vinci are quite different. So depending on what the mix of private and public is, and what the government-run hospitals are wanting to do, we'll see different dynamics and behavior.
簡短回答:是的,差異很大。你會看到幾個不同因素。而且我認為你必須分別去看:義大利發生什麼、西班牙發生什麼、德國發生什麼、法國發生什麼、英國發生什麼、北歐國家發生什麼。它們彼此不同。在許多國家,你會看到私營醫療體系與公營體系並存。它們對da Vinci的行為模式差異很大。因此取決於私營與公營的組合比例,以及政府經營的醫院想要怎麼做,我們會看到不同的動態與行為。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then last one, as we think about some of the gives and takes around procedures, understand obviously you didn't change guidance on procedures this year. But do you see a path north of 30% in the medium to intermediate term the next couple of years, given everything you've got in terms of new procedures? I don't want to box you into giving longer-term guidance, but how do you think about where procedures could go?
最後一個問題,當我們思考手術量的此消彼長時,理解你今年顯然沒有調整對手術量的指引。但在未來中期到中短期、接下來幾年,考量你們在新術式方面的所有進展,你是否看到手術量成長率有機會高於30%的路徑?我不想把你框進必須給出更長期指引,但你怎麼看手術量可能走到哪裡?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Our best thoughts are in the guidance we provide you.
我們最好的看法都已反映在我們提供給你們的指引中。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
I was talking beyond this year, though.
不過我是在談今年以後。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
And we'll talk to you about that in January.
我們會在一月再跟你談這件事。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
David Lewis with Morgan Stanley.
Morgan Stanley的David Lewis。
David Lewis - Analyst
David Lewis - Analyst
Gary, these comments about the DVP in the US, most of the comments so far have really focused on utilization or patient demand creation. I wonder, have you seen anything in the US that would suggest that maybe it's push and pull, where it's a hospital-specific issue? I'm really referring to ACOs' demonstration projects, where the hospitals are targeting prostatectomy for its declining profitability or something like that. Or this is very acutely the patients just aren't proceeding to surgery and aren't showing up?
Gary,關於美國DVP的這些評論,到目前為止多數都聚焦在使用率或病患需求的創造。我想問的是,你是否在美國看到任何跡象顯示這可能是拉鋸的結果、也就是醫院層級的特定問題?我指的是ACO示範專案,醫院可能因為前列腺切除術獲利能力下降之類的原因,而把它列為目標來處理。還是說這非常明確就是病患不再繼續走向手術、也沒有來就診?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Without having talked to every hospital in the US, I have not heard the concern that you just voiced, that hospitals is trying to direct patients one way or the other due to their perceived profitability. Generally speaking, most hospitals will offer both, or all three alternatives. They will counsel all of them. And in that setting, where all the alternatives are discussed, and a patient has been diagnosed, da Vinci does well. And we've seen a lot of stability there. So short answer is it tends to be more diagnosis and nonsurgical approaches than it is, I think, directed intervention.
在沒有跟美國每一家醫院都談過的前提下,我沒有聽到你剛才提出的那種擔憂,也就是醫院因為其認知的獲利能力而試圖把病患導向某一種選擇。一般而言,多數醫院會同時提供兩種,或三種替代方案。他們會對所有方案進行諮詢說明。在那種情境下,當所有替代方案都被討論、且病患已被診斷時,da Vinci的表現很好。我們也看到那裡相當穩定。所以簡短回答是:這更偏向於診斷量與非手術治療方式,而不是我認為的那種被導向的介入。
David Lewis - Analyst
David Lewis - Analyst
Very helpful. And the clear positive this quarter on the capital side in the US is multiple capital peers have reported softness in the second quarter. You don't appear to have exhibited any of that softness. Is it safe to assume that you feel, at least as far as the second quarter is concerned, relatively insulated from some of the factors that may have been out there, or some of the pushouts that some of your peers have seen in the second quarter?
非常有幫助。而本季在美國資本設備端明顯的正面訊號是,多家同業資本設備公司都回報第二季疲軟。你們看起來並沒有出現那種疲軟。是否可以合理推論,至少就第二季而言,你們覺得自己相對不受一些可能存在的因素影響,或不太受到同業在第二季所看到的延後(pushouts)影響?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Again, I think the term insulated has got a few meanings. But I would say that if you look at -- and again, back away from just that number for a second and look at the overall procedure business. We've reported a 26% gain in procedures year-over-year, and for the first half of the year, it's up 27%. That's still a pretty large number. And so that does necessitate the demand for systems. And so we do believe that. We do believe that very strongly. I don't think there was a particular event or an episode in Q2 that separated us from our peer group or other capital companies any more than just strong procedure demand.
同樣地,我認為「不受影響(insulated)」這個詞有幾種含義。但我會說,如果你看——再退一步,不只看那個數字,而是看整體手術量業務。我們回報手術量年增26%,而上半年累計成長27%。這仍然是相當大的數字。因此確實會帶動對系統的需求。所以我們相信這一點。我們非常堅信。我不認為第二季有某個特定事件或插曲讓我們比同業或其他資本設備公司更「脫鉤」,更多只是強勁的手術量需求。
Now, there are, as you said earlier, puts and takes on the procedures. While one has gone down, several have gone up. And some have gone up pretty significantly. And on balance, it's a very strong procedure business. And I think that's really what separates us from some of the other companies that are up there when you look at the actual numbers and the percentage of growth. So short of that, I don't think there's anything else we can really point to.
如你先前所說,手術量確實有此消彼長。當其中一項下降時,有幾項上升。而且有些上升幅度相當顯著。整體而言,手術量業務非常強勁。我認為這才是真正讓我們與其他公司拉開差距的地方,當你看實際數字與成長百分比時就會明顯。除此之外,我不認為我們還能指出其他因素。
David Lewis - Analyst
David Lewis - Analyst
And just Gary, maybe just one quick one, if I could. In the comments about Europe, I wonder, have you seen anything in Europe over the last couple quarters or several quarters that would suggest that perhaps the market development in Europe is going to be different than the US in one particular way. Which would be, in the US, you never engaged in a directed significant study to prove a specific procedure. But you had a wealth of single-center experience data and multi-center experience data that was generated by users. Is there a sense, based on what you're seeing in Europe, that a more directed or active approach to clinical data is going to be required in Europe? Or is that not the case?
Gary,最後也許再一個很快的小問題,如果可以的話。在談到歐洲時,我想問:你是否在過去幾季或更長一段時間看到任何跡象,顯示歐洲的市場發展可能會在某個特定面向上不同於美國?也就是,在美國你們從未進行一項被導向、且規模重大的研究來證明某一特定術式。但你們有大量由使用者產生的單一中心經驗數據與多中心經驗數據。根據你在歐洲看到的情況,是否有一種感覺是:在歐洲需要更被導向或更積極的臨床數據策略?還是其實不是這樣?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think a more active conversation is required. And that's a little bit of what we've been talking about with regard to the health technology assessments and other things. Now we've been in the market long enough, in some procedures over a decade, that there's actually large population-based studies that are well done, multi-center, tens of thousands of patients in them, that show clear benefits for da Vinci over other surgical alternatives. There's data being generated around comparisons to other treatment modalities, between da Vinci surgery and nonsurgical outcomes. I think that data is going to be helpful worldwide and in Europe. There may be cases, and certainly we're in conversation and have thoughts and plans around specific trials that may help us in different locales, and Europe is one of them.
我認為需要更積極的對話。這也正是我們一直在談的部分內容,涉及健康技術評估(health technology assessments)以及其他事項。現在我們在市場上的時間已經夠久了,某些術式甚至超過十年,因此其實已經有以大型人群為基礎、做得很好的研究,多中心、納入數以萬計的病患,清楚顯示da Vinci相較其他手術替代方案的效益。也有數據正在產生,用於與其他治療方式做比較,包括da Vinci手術與非手術治療結果之間的比較。我認為這些數據在全球以及在歐洲都會有幫助。可能會有一些情況——而且我們確實正在討論,並且對特定試驗有一些想法與計畫——這些試驗可能在不同地區對我們有所幫助,歐洲就是其中之一。
David Lewis - Analyst
David Lewis - Analyst
Great. Thank you very much.
很好。非常感謝。
Operator
Operator
Larry Keusch with Raymond James.
Raymond James 的 Larry Keusch。
Larry Keusch - Analyst
Larry Keusch - Analyst
Just to pick up on Europe, Gary, I think I heard you correctly. It sounded like there's a change in the leadership there. And if I caught that accurately, if you could just walk us through what's changing and what's the strategic direction.
Gary,我想接續一下歐洲的話題,我應該沒聽錯。聽起來那邊的領導層有變動。如果我理解正確的話,能否請你帶我們梳理一下有哪些改變,以及策略方向是什麼。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes. So we have changed leadership in terms of the leadership of the commercial organization in the direct side of Europe. As well as overall leadership over the indirect, as well. This is somebody who has been with us for many years in the US and that had run the national account side of the business here in the United States. Knows our business very well, has had prior experiences in Europe. And so he'll be taking over there.
是的。所以我們在歐洲直銷端的商業組織領導方面做了調整。同時也調整了對間接通路的整體領導。這位同仁在美國與我們共事多年,曾負責美國這邊業務的全國客戶(National Accounts)部門。非常了解我們的業務,也曾有在歐洲的相關經驗。因此他將接手那邊的工作。
Larry Keusch - Analyst
Larry Keusch - Analyst
But part of the question is, is that the result of the current environment or needing to change your strategic tactics within Europe, coming back to needing more discussions around the marketing of the device and the procedures? Just trying to understand perhaps what there may be in the change in strategy in the European region.
但我想問的是,這是因為目前環境所致,還是你們需要在歐洲調整策略戰術,例如回到需要更多關於裝置與手術行銷的討論?我只是想了解,歐洲區域的策略改變可能會是什麼。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think it's probably less a capitalized strategy change and more a focus on execution and organizational growth and capability. There are some things that we can do a little bit differently and perhaps a little bit better in terms of some of the conversations on the economic side. Small strategy. I don't think it's earth shatteringly different, but I do think it's an emphasis change. And we're working on those things.
我認為這與其說是重大的策略改變,不如說是更聚焦在執行力、組織成長與能力建置。在經濟性(health economics)層面的溝通上,有些事情我們可以做得稍微不同、也可能更好一些。算是小幅策略調整。我不認為會有翻天覆地的不同,但我確實認為重點有所轉移。我們正在推進這些工作。
Larry Keusch - Analyst
Larry Keusch - Analyst
Okay, great. And then, obviously it's terrific to hear that the Single-Site procedures are starting to gain some traction. And I fully understand it's going to take a couple quarters to fully feel that out. The conversations that we've had with folks would suggest that, where there is a da Vinci in place, the general surgeons are eager to jump in and get some time on the system to try out these procedures. And generally we have heard very good things once they get to do it. But the question that I wrestle with is, there's an awful lot of general surgical procedures, prostatectomies in particular, that are probably done in institutions that to date don't have a da Vinci system. So can you make a convincing ROI argument that this system can be used for general surgery, as a stand-alone device, even with the SIE option? Or at some point does it have to be a segmentation strategy?
好的,很棒。另外,很高興聽到 Single-Site 手術開始有些進展。我完全理解要花幾個季度才能真正看出成效。我們與一些人士的對話顯示,在已經有 da Vinci 的地方,一般外科醫師很想加入並在系統上取得一些操作時間來嘗試這些手術。而且通常一旦他們實際做過之後,我們聽到的回饋都非常好。但我糾結的問題是,有非常多的一般外科手術,尤其是前列腺切除術,可能是在目前仍沒有 da Vinci 系統的機構中進行。所以你們能否提出一個有說服力的投資報酬率(ROI)論點,讓這套系統即使搭配 SIE 選項,也能作為一般外科的單一用途設備來使用?或者在某個時間點,是否必須採取市場區隔(segmentation)策略?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Larry, if you look at the overall number of da Vinci placements in the United States, we have 1,707 total systems. And I believe the number of US customers -- Calvin will give it to us -- I believe it's somewhere 1,200 to 1,300, I believe.
Larry,如果你看美國整體 da Vinci 的裝機數,我們總共有 1,707 套系統。我相信美國客戶數——Calvin 會告訴我們——我認為大概在 1,200 到 1,300 之間。
Calvin Darling - Sr. Dir. IR
Calvin Darling - Sr. Dir. IR
1,275.
1,275。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
1,275. What we have seen in prostatectomy, for example, is that the system has, to this point, become somewhat of a consolidator for the procedure, rather than having to put systems in all 4,800 or 5,000 hospitals that are out there. You have seen a strong consolidation of, let's say, the urologic oncology business happen around the same base of systems that prior to minimally-invasive introduction was being done at significantly more hospitals. Fewer were being done at more hospitals. So I don't think we look at it and say, can we necessarily build this self-standing platform with general surgery as a paramount question today.
1,275。以前列腺切除術為例,我們看到的是,到目前為止,這套系統在某種程度上成為該手術的「集中器」(consolidator),而不是必須把系統部署到外面所有 4,800 或 5,000 家醫院。你已經看到泌尿腫瘤(urologic oncology)業務在同一批系統基礎上出現強烈的集中化;在微創技術導入之前,這些手術其實分散在更多家醫院進行。也就是說,手術量更集中、但醫院數更少。所以我不認為我們今天看待的核心問題是:能否靠一般外科把它打造成一個完全自立的平臺。
Now, what we do believe is with the increased interest, both from the colorectal surgeon, from other complex general surgery procedures, as well as the individual cholecystectomy procedures, that there is enough capacity out there for people to actually try, use it, and then build into the flow of the robotics coordinators in the hospital to make sure that there's enough access, whether it becomes second systems or third systems, et cetera. But the cholecystectomies by themselves is probably not the way we think about it. I think general surgery as a whole, and then leveraging the installed base that we have.
不過,我們確實相信,隨著結直腸外科醫師、其他複雜一般外科手術,以及個別膽囊切除術的興趣提升,市場上有足夠的產能讓大家去嘗試、使用,並逐步納入醫院機器人協調員(robotics coordinators)的排程流程,確保有足夠的使用時段;未來是否會變成第二套、第三套系統等等。但單靠膽囊切除術本身,可能不是我們思考的方式。我認為應該從「一般外科整體」來看,並善用我們既有的裝機基礎。
Larry Keusch - Analyst
Larry Keusch - Analyst
Okay, understood. And then just last one. And not to continue to come back to US prostatectomy, but any flavor for where US prostatectomy procedures -- I assume they were down sequentially. Would you characterize it as a sharp falloff relative to where we've been over the last couple quarters? Or, it's been a gradual decline and now we've hit a point where we're down year over year?
好的,了解。最後一個問題。我不是要一直回到美國前列腺切除術,但能否談談美國前列腺切除術的手術量——我假設它是季對季下滑。你會把它形容為相較於過去幾個季度是明顯的急跌嗎?還是一直是逐步下滑,現在才來到年對年為負的狀態?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
I think the way we think about it, and really what the numbers will tell us, that it's been a gradual decline over the past few quarters. We've called it out in the past. And now we're calling it out with a little more emphasis. And there appears to be more evidence in the macro environment for prostate cancer that we can refer to with a little more clarity.
我認為我們的看法,以及數據真正會告訴我們的是:過去幾個季度一直是逐步下滑。我們之前就提過。而現在我們用更強的語氣再度提出。而且在前列腺癌的宏觀環境方面,似乎有更多證據讓我們能更清楚地引用與說明。
Larry Keusch - Analyst
Larry Keusch - Analyst
Okay, great. Thanks very much.
好的,很棒。非常感謝。
Operator
Operator
Jose Haresco with JMP Securities.
JMP Securities 的 Jose Haresco。
Jose Haresco - Analyst
Jose Haresco - Analyst
Couple questions. On Single-Site choli, you guys haven't broken this out in the past. But are you at a point where you can give us a sense of how many procedures you think you've done in Single-Site choli? Or just in general, how many Single-Site procedures have been done since these 200 devices have been placed out there?
兩個問題。關於 Single-Site 膽囊切除(choli),你們過去沒有把這個拆開揭露。但你們現在是否已經可以讓我們大概了解,你們認為已經做了多少例 Single-Site 膽囊切除手術?或者更一般地說,自從這 200 台裝置部署出去以來,總共做了多少例 Single-Site 手術?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We're not ready yet to start breaking that out, just because we're still in the early days of seeing new sites come up and really work through their initial orders. What we would like to see is what happens on a sustained basis, how much of their future business they start to convert to Single-Site and so on. And that's just too early to tell. We're happy to talk a little bit qualitatively about how the initial installs are going, but we'll wait a little bit on sequential use. There's probably time for one more question.
我們還沒準備好開始拆分揭露,因為我們仍處於早期階段,正在觀察新據點上線,並真正走完他們的初期訂單流程。我們希望看到的是:在可持續的基礎上會發生什麼,他們未來的業務有多少會開始轉換到 Single-Site 等等。現在判斷還太早。我們很樂意從質性角度談談初期安裝的進展,但在連續使用(sequential use)方面我們會再等一等。大概還有時間再問一個問題。
Jose Haresco - Analyst
Jose Haresco - Analyst
Sure. Just on Europe, trying to get a little bit more. Can you give us a little bit more granularity between, say, regions of Europe, Southern Europe versus Western Europe as an example, and then procedures versus hardware? You guys raised the system guidance, I read in your guidance for the year. So I want to get a better sense for where that confidence is coming from, beyond just the slight increase in ASP that we saw in the quarter.
好的。再回到歐洲,我想再多了解一些。你能否更細緻地拆解一下,例如南歐相對於西歐等不同區域,以及手術量相對於硬體(設備)之間的情況?我看到你們在今年的指引中上調了系統(出貨/裝機)指引。所以我想更清楚了解,這份信心來源是什麼,除了本季我們看到 ASP 小幅上升之外。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
On the breakouts country by country, it's a little bit mix. Probably not real surprising that some of the countries in the south that are always in the news have been most strained in terms of both system sales and procedures. Although I would say that Italy has been a bright spot. We have seen some pressure in both capital and procedures in some of the core countries of Europe, as well. And that's where we are and what we're working through.
就各國逐一拆分來看,情況有點參差不齊。一些南歐國家經常出現在新聞中,無論在系統銷售或手術量方面承受的壓力最大,這大概也不令人意外。不過我會說,義大利一直是個亮點。我們也在歐洲一些核心國家看到資本支出與手術量兩方面的壓力。目前就是這樣的狀況,也是我們正在努力消化與應對的部分。
Jose Haresco - Analyst
Jose Haresco - Analyst
Okay, great. Thank you very much.
好的,很棒。非常感謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you. That was our last question. As we have said previously, while we focus on financial metrics, such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing patient value by improving surgical outcomes and reducing surgical trauma.
謝謝。那是我們最後一個問題。如同我們先前所說,雖然在這些電話會議中我們會聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過改善手術結果並降低手術創傷,來提升病患價值。
I hope the following experience from Rebecca in Maryland gives you some sense of what this means in the lives of our patients. Quote -- I went to Dr. Katherine Kratz upon discovering that I had a uterine fibroid and endometrial cyst which had been causing painful menstrual cramps, as well as severe lower back pain. Dr. Kratz recommended da Vinci surgery for several reasons. The procedure is minimally invasive, so the recovery time would be much quicker. At the time, I was trying to finish up my dissertation and apply for academic jobs. So it was important to me to have a quick recovery. My surgeon also explained that this procedure allows for greater visualization of the area. As well as providing her a greater range of motion. Allowing her to work with great precision in performing the surgery and in doing the stitches. Because of this, Dr. Kratz was able to save my left ovary, which would not have been possible otherwise.
我希望接下來來自馬里蘭州 Rebecca 的經驗,能讓各位對這在病患生活中代表的意義有些感受。引述——我在發現自己有子宮肌瘤與子宮內膜囊腫後,前往找 Katherine Kratz 醫師就診;這些問題一直造成經痛,以及嚴重的下背痛。Kratz 醫師基於幾個原因建議採用達文西手術。這項手術屬於微創,因此復原時間會快得多。當時我正努力完成我的博士論文,並申請學術工作。所以對我而言,快速復原非常重要。我的外科醫師也解釋,這項手術能讓手術區域的視野更清楚。同時也能讓她有更大的活動範圍。使她在進行手術與縫合時,能以極高的精準度操作。因此,Kratz 醫師得以保住我的左側卵巢,否則是不可能做到的。
After my surgery, not only was I able to return to working on my dissertation within a few days, but I was also able to attend my annual professional conference a few weeks later. Even with all that I had been told, I was shocked at how quickly I had recovered from surgery. Every day I was able to move more easily and with far less pain, allowing me to stop taking pain medication after a day or two. Now I am free of back pain and have nearly no menstrual cramps. I'm extremely grateful for the da Vinci surgery and the excellent care I received from Dr. Kratz and her entire surgical team because the surgery has significantly improved my quality of life. When I look back at that time of my life, I have only positive memories of my surgical experience. My surgeon provided me with comprehensive information about my options and about the surgery. And allowed me to make the decision that was best for my situation. End quote. Patients like these are the strongest advocates for da Vinci surgery and form the very foundation of our operating performance. We have built our Company to take surgery beyond the limits of the human hand. And I assure you that we remain committed to driving (inaudible) a few things that truly make a difference. This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery. And we look forward to talking with you again in three months.
手術後,我不僅在幾天內就能回去繼續寫論文,幾週後也能參加我每年的專業年會。即使事前已被告知許多,我仍對自己從手術中恢復得如此之快感到震驚。每天我都能更輕鬆地活動,疼痛也少得多,讓我在一兩天後就能停止服用止痛藥。現在我已不再有背痛,經痛也幾乎沒有了。我非常感謝達文西手術,以及 Kratz 醫師與她整個手術團隊給我的優質照護,因為這次手術大幅提升了我的生活品質。回想那段人生時期,我對這次手術經驗只留下正面的回憶。我的外科醫師向我提供了關於各種選項與手術本身的完整資訊。並讓我能做出最符合自身情況的決定。引述結束。像這樣的病患,是達文西手術最有力的倡議者,也構成我們營運表現最根本的基礎。我們打造公司,是為了讓手術突破人類雙手的極限。我向各位保證,我們仍致力於推動(聽不清)幾件真正能帶來改變的事情。今天的電話會議到此結束。感謝各位在這段非凡的改善手術旅程中參與並支持我們。我們期待三個月後再與各位交流。
Operator
Operator
Ladies and gentlemen, that does conclude your conference for today. Thank you for your participation, and for using AT&T executive teleconference service. You may now disconnect.
各位女士、先生,今天的電話會議到此結束。感謝各位的參與,並使用 AT&T 高階主管電話會議服務。您現在可以掛線。